Figure 3.

The relevance of haploproficiency and hypertolerance to drug interventions. a) specific inhibition, but not complete protein-product ablation, of an HP target prompts increased growth; b) case where the cancer cell itself bears a CNV of an HP gene, the deletion mutant phenotype may better predict cancer cell drug response; c) case where the deletion mutant for a specific gene is hypertolerant to a compound inhibiting a distinct target, a combination therapy of the same compound plus an inhibitor of the first gene is unlikely to elicit a positive therapeutic response.

de Clare and Oliver BMC Biology 2013 11:24   doi:10.1186/1741-7007-11-24
Download authors' original image